

**Listing of Claims**

1. **(original)** An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding VCC-1, wherein said antisense compound specifically hybridizes with and inhibits the expression of VCC-1.
2. **(original)** The antisense compound of claim 1 which is an antisense oligonucleotide.
3. **(original)** The antisense oligonucleotide of claim 2 comprising a nucleic acid sequence selected from the group consisting of at least eight contiguous bases of SEQ ID NO: 1 – SEQ ID NO: 1099.
4. **(original)** The antisense oligonucleotide of claim 2 comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 – SEQ ID NO: 1099.
5. **(currently amended)** The antisense compound of claim 2 **[[, 3, or 4]]** wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
6. **(original)** The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.
7. **(currently amended)** The antisense compound of claim 2 **[[, 3, or 4]]** wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
8. **(original)** The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
9. **(currently amended)** The antisense compound of claim 2 **[[, 3, or 4]]** wherein the antisense oligonucleotide comprises at least one modified nucleobase.

10. **(original)** The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

11. **(currently amended)** The antisense compound of claim 2 **[[, 3, or 4]]** wherein the antisense oligonucleotide is a chimeric oligonucleotide.

12. **(original)** A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. **(original)** The composition of claim 12 further comprising a colloidal dispersion system.

14. **(original)** The composition of claim 13 wherein the antisense compound is an antisense oligonucleotide.

15. **(original)** A method of inhibiting the expression of VCC-1 in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of VCC-1 is inhibited.

16. **(original)** A method of treating a human having a disease or condition associated with VCC-1 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of VCC-1 is inhibited.

17. **(currently amended)** The method of claim 16 wherein the disease or condition **is selected from the group consisting of diabetes, an immunological disorder, a cardiovascular disorder, a neurologic disorder, an ischemia/reperfusion injury, any form of cancer, and an angiogenic disorder.**

**Claims 18-21 (canceled)**

22. **(original)** The method of claim 16 wherein the disease or condition is any form of cancer.

23. **(original)** The method of claim 16 wherein the disease or condition is an angiogenic disorder.